185 related articles for article (PubMed ID: 11597832)
1. Matrix metalloproteinase inhibition and the prevention of heart failure.
Lee RT
Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
3. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
5. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
Peterson JT; Hallak H; Johnson L; Li H; O'Brien PM; Sliskovic DR; Bocan TM; Coker ML; Etoh T; Spinale FG
Circulation; 2001 May; 103(18):2303-9. PubMed ID: 11342481
[TBL] [Abstract][Full Text] [Related]
7. MMP induction and inhibition in myocardial infarction.
Lindsey ML
Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model.
Mori S; Gibson G; McTiernan CF
J Card Fail; 2006 May; 12(4):314-25. PubMed ID: 16679266
[TBL] [Abstract][Full Text] [Related]
9. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
10. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
[TBL] [Abstract][Full Text] [Related]
11. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
12. Loss of PI3Kγ enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress.
Guo D; Kassiri Z; Basu R; Chow FL; Kandalam V; Damilano F; Liang W; Izumo S; Hirsch E; Penninger JM; Backx PH; Oudit GY
Circ Res; 2010 Nov; 107(10):1275-89. PubMed ID: 20847309
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases: pathways of induction by bioactive molecules.
Tsuruda T; Costello-Boerrigter LC; Burnett JC
Heart Fail Rev; 2004 Jan; 9(1):53-61. PubMed ID: 14739768
[TBL] [Abstract][Full Text] [Related]
14. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition.
Li H; Simon H; Bocan TM; Peterson JT
Cardiovasc Res; 2000 May; 46(2):298-306. PubMed ID: 10773234
[TBL] [Abstract][Full Text] [Related]
15. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
[TBL] [Abstract][Full Text] [Related]
16. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
Vanhoutte D; Heymans S
J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
[TBL] [Abstract][Full Text] [Related]
17. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
Peterson JT; Li H; Dillon L; Bryant JW
Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis.
Friehs I; Margossian RE; Moran AM; Cao-Danh H; Moses MA; del Nido PJ
Basic Res Cardiol; 2006 May; 101(3):204-13. PubMed ID: 16369727
[TBL] [Abstract][Full Text] [Related]
20. Myocardial extracellular matrix remodeling in ischemic heart failure.
Gallagher GL; Jackson CJ; Hunyor SN
Front Biosci; 2007 Jan; 12():1410-9. PubMed ID: 17127391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]